Brett E. Houk

Brett E. Houk

Auto-generated profile, based on publicly available information

Brett E. Houk

Clinical Pharmacology Modeling and Simulation Amgen Inc. Thousand Oaks California USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
LALubna Abuqayyas
Lubna Abuqayyas
PCPo-Wei Chen
Po-Wei Chen
MSMarcia Teixeira dos Santos
Marcia Teixeira dos Santos
JPJane R. Parnes
Jane R. Parnes
SDSameer Doshi
Sameer Doshi
BHBrett E. Houk
Brett E. Houk
Rozibafusp alfa (AMG 570) is a first‐in‐class bispecific IgG2‐peptide fusion designed to inhibit inducible T‐cell costimulator ligand (ICOSL) and B‐cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in two randomized, placebo‐controlled clinical studies: a phase Ia single ascending‐dose study (7–700 mg subcutaneously (s.c.)) in healthy subjects and a phase Ib multiple ascending‐dose study (70–420 mg s.c. every 2 weeks (q2w)) in patients with rheumatoid arthritis. Rozibafusp alfa exhibited nonlinear PK and dose‐related and reversible dual‐target engagement. Maximal reduction of naïve B cells from baseline (> 40%), reflective of BAFF inhibition, was achieved with rozibafusp alfa exposure (area under the concentration‐time curve from time 0 to time infinity (AUCinf) and AUC within a dosing interval from day 0 to day 14 (AUCtau)) above 51 and 57 days•μg/mL for the single‐dose (≥ 70 mg) and multiple‐dose studies (≥ 70 mg q2w), respectively. ICOSL receptor occupancy on circulating B cells, a surrogate PD end point for ICOSL inhibition, was directly related to drug concentration. PK/PD analysis showed > 90% RO at rozibafusp alfa ≥ 22.2 μg/mL (≥ 420‐mg single dose or ≥ 210 mg q2w multiple dose), with saturation occurring at higher drug concentrations. These results informed the design and dose selection of a phase IIb study assessing the safety and efficacy of rozibafusp alfa in patients with active systemic lupus erythematosus.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AFAndres Forero-Torres
Andres Forero-Torres
HHHeather Han
Heather Han
EDElizabeth Claire Dees
Elizabeth Claire Dees
RWRobert Wesolowski
Robert Wesolowski
ABAditya Bardia
Aditya Bardia
HRHope Rugo
Hope Rugo
1040 Background: The majority of women with ER+ MBC develop resistance to ET. ET plus a CDK4/6 inhibitor (CDKi 4/6) demonstrate improved progression-free survival (PFS) in first/later line MBC. Preclinical evidence in PI3K mutant cell-line xenografts (PIK3CA) supported developing a triplet combination of gedatolisib (G), a dual inhibitor of PI3K/mammalian target of rapamycin (mTOR), with CDKi 4/6 palbociclib (P)+letrozole (L) or fulvestrant (F) for patients (pts) with ER+/HER2- MBC. Methods: This ongoing dose escalation/expansion study in pts with ER+/HER2- MBC, in first/later line MBC, evaluates dose-limiting toxicities/recommended phase 2 dose (DLTs/RP2D) for triplet regimens of G+P+L or G+P+F. A 3-arm expansion investigates objective response rate (ORR) compared to historical controls of Arm A) G+P+L in first-line, B) G+P+F in pts with no prior CDKi 4/6 in second-line and C) G+P+F in pts with prior CDKi 4/6. Pts receive G (180 mg IV/week) combined with P+L or P+F at standard of care doses. Secondary endpoints include safety, ORR, PFS, and pharmacokinetics (PK); exploratory endpoints include genomic analysis of PI3K/mTOR pathway. Results: 35 pts received G at RP2D of 180 mg with P+L (n = 15) or P+F (n = 20). Median numbers of prior therapies: G+P+L: 2 (range: 1-2); G+P+F: 1 (range 1-3). Most common (≥50%), drug-related adverse events (%): G+P+L: nausea (80), stomatitis (73), fatigue (60), neutropenia (60), dysgeusia (53); G+P+F: stomatitis (70), fatigue (70), neutropenia (60), nausea (60), dysgeusia (55). Cycle 1 DLTs: G+P+L: grade (gr) 3 neutropenia (n = 2), gr 3 stomatitis (n = 1), gr 3 febrile neutropenia (n = 1); G+P+F: gr 3 stomatitis (n = 2), gr 3 mucositis (n = 1), gr 3 abdominal pain (n = 1). Preliminary stable disease/partial response: G+P+L: 53%/33%; G+P+F: 55%/20%. No PK interactions were observed. PIK3CA and ER mutation status from circulating free deoxyribonucleic acid and duration of response will be reported. Genomic analysis of tumor tissue is underway. Conclusions: G can be combined with P+L or P+F with manageable toxicity and promising preliminary antitumor activity. Dose escalation is completed and expansion is ongoing. Clinical trial information: NCT02684032.

26 November 2024 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
MMMukul Minocha
Mukul Minocha
CTCorbin G. Thompson
Corbin G. Thompson
AMAlexis Murphy
Alexis Murphy
YZYanchen Zhou
Yanchen Zhou
CBChristian Brandl
Christian Brandl
BHBrett E. Houk
Brett E. Houk

18 December 2022 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
IVIrene Vuu
Irene Vuu
JWJan L. Wahlstrom
Jan L. Wahlstrom
BHBrett E. Houk
Brett E. Houk

10 September 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
PCPo-Wei Chen
Po-Wei Chen
MMMukul Minocha
Mukul Minocha
SKStephanie Kong
Stephanie Kong
TJTony Jiang
Tony Jiang
EAErik S. Anderson
Erik S. Anderson
CLChih-Wei Lin
Chih-Wei Lin
Purpose: Tarlatamab is a first-in-class, half-life extended bispecific T-cell engager immunotherapy targeting delta-like ligand 3, currently approved for the treatment of adult patients with small cell lung cancer with disease progression on or after platinum-based chemotherapy. In this study, we report tarlatamab exposure–response relationships to inform dose selection in patients with small cell lung cancer. Patients and Methods: Pharmacokinetic data were correlated with therapeutic effect (exposure–response analyses) for efficacy and safety measures using pooled data from the DeLLphi-300 and DeLLphi-301 studies. Efficacy measures included objective response rate, disease control rate, best change from baseline in tumor size, progression-free survival, and overall survival. Safety events included treatment-emergent adverse events (TEAE), treatment-related adverse events, and TEAE of interest, including cytokine release syndrome, neutropenia, and neurologic toxicity such as immune effector cell–associated neurotoxicity syndrome. Effects of patient-specific factors were also assessed. Doses ranging from 0.003 to 100 mg every 2 weeks and 200 mg every 3 weeks were explored. Results: Significant positive exposure–response relationships were established for all evaluated efficacy measures. Near-maximal efficacy was reached at exposures associated with the clinical regimen of 10 mg every 2 weeks. No relationships with exposure were identified for the following grade ≥3 events: TEAE, treatment-related adverse events, cytokine release syndrome, and neurologic toxicity, including immune effector cell–associated neurotoxicity syndrome. A shallow trend was observed for a higher percentage of patients experiencing grade ≥3 neutropenia with higher exposures. Conclusions: This analysis supports a 10-mg every-2-weeks regimen and that no dose adjustment is necessary based on age, race, body weight, immunogenicity, number of prior therapies, or disease burden.

21 May 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
BHBrett E. Houk
Brett E. Houk